[1] Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, et al.Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021; 27(8):1862-1880.
[2] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100(Pt E):1-538.
[3] IARC Monographs Vol 128 group. Carcinogenicity of acrolein, crotonaldehyde, and arecoline Vol 128 group. Carcinogenicity of acrolein, crotonaldehyde, and arecoline. Lancet Oncol. 2021; 22(1):19-20.
[4] Chiang WF, Liu SY, Lin JF, et al.Malignant development in patients with oral potentially malignant disorders detected through nationwide screening: Outcomes of 5-year follow-up at a single hospital. Head Neck. 2020; 42(1):67-76.
[5] Chuang SL, Wang CP, Chen MK, et al.Malignant transformation to oral cancer by subtype of oral potentially malignant disorder: A prospective cohort study of Taiwanese nationwide oral cancer screening program. Oral oncology. 2018; 87: 58-63.
[6] Yang PY, Chen YT, Wang YH, et al.Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study. Oral Pathol Med, 2017; 46(10):1040-1045.
[7] Mohiuddin S, Fatima N, Hosein S, et al.High risk of malignant transformation of oral submucous fibrosis in Pakistani females: A potential national disaster. Pak Med Assoc, 2016;66(11):1362-1366.
[8] 杜永秀,孙东业,翦新春等.咀嚼槟榔种类与口腔黏膜疾病的流行病学调查分析[J].华西口腔医学杂志,2016, 34(4):391-394.
[9] Chourasia NR, Borle RM, Vastani A.Concomitant Association of Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma and Incidence of Malignant Transformation of Oral Submucous Fibrosis in a Population of Central India: A Retrospective Study. Maxillofac Oral Surg, 2015; 14(4):902-906.
[10] Wang YY, Tail YH, Wang WC, et al.Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health, 2014; 14:99.
[11] Hazarey VK, Erlewad DM, Mundhe KA, et al.Oral submucous fibrosis: study of 1000 cases from central India. Oral Pathol Med. 2007; 36(1):12-17.
[12] Hsue SS, Wang WC, Chen CH, et al.Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital.Oral Pathol Med, 2007; 36(1):25-29.
[13] 高义军,凌天牗,尹晓敏等.口腔黏膜下纤维性变癌变的回顾性研究[J].临床口腔医学杂志,2005, 21(2):119-120.
[14] Tang JG, Jian XF, Gao ML, et al.Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan Province, China. Community Dent Oral Epidemiol, 1997; 25(2):177-180. [15] Murti PR, Bhonsle RB, Pindborg JJ, et al. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol, 1985; 13(6):340-341.
[16] 周晌辉,胡延佳,周艳宏,等. 口腔黏膜下纤维性变癌变危险因素的Logistic回归分析[J]. 中国医学工程, 2007, 15(5):407-409,412.
[17] 肖艳波,尹晓敏,高义军.口腔黏膜下纤维性变癌变的相关危险因素分析[J].中国现代医学杂志, 2011, 21(21):2648-2651.
[18] 刘博闻. 湖南地区口腔粘膜下纤维性变癌变危险因素病例对照研究[D].湖南:中南大学, 2012. DOI:10.7666/d.y2198585
[19] 李春海,李克勤.肿瘤微血管生成的机制与肿瘤侵袭和转移[J].中华肿瘤杂志,2000(03):5-7 .
[20] Pereira T, Surve R, Shetty S, et al.Qualitative expression of hypoxia-inducible factor-1α in malignant transformation of oral submucous fibrosis: An immunohistochemical study.Oral Maxillofac Pathol, 2020; 24(1):106-112.
[21] Chaudhary M, Bajaj S, Bohra S, et al.The domino effect: Role of hypoxia in malignant transformation of oral submucous fibrosis. Oral Maxillofac Pathol, 2015; 19(2):122-127.
[22] Tilakaratne WM, Iqbal Z, Teh MT, et al.Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis. Oral Pathol Med, 2008; 37(6):372-377.
[23] Joseph I, Elizabeth J, Rao UK, Ranganathan K.Study of Hypoxia-inducible factor-2α expression in the malignant transformation of Oral submucous fibrosis. Oral Maxillofac Pathol, 2020; 24(1):33-39.
[24] Anura A, Das RK, Pal M, et al.Correlated analysis of semi-quantitative immunohistochemical features of E-cadherin, VEGF and CD105 in assessing malignant potentiality of oral submucous fibrosis. Pathol Res Pract,2014; 210(12):1054-1063.
[25] Das RK, Pal M, Barui A, et al.Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expression. J Clin Pathol, 2010; 63(10):894-899.
[26] Tang MKS, Yue PYK, Ip PP, et al.Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat Commun, 2018; 9(1):2270.
[27] Desai RS, Mamatha GS, Khatri MJ, et al.Immunohistochemical expression of CD34 for characterization and quantification of mucosal vasculature and its probable role in malignant transformation of atrophic epithelium in oral submucous fibrosis. Oral Oncol, 2010; 46(7):553-558.
[28] 刘偲璇,全宏志. 口腔鳞状细胞癌合并口腔黏膜下纤维性变患者的免疫表达特征[A]. 中华口腔医学会口腔生物医学专业委员会.2020年中华口腔医学会口腔生物医学专业委员会第十次全国口腔生物医学学术年会暨第六次全国口腔杰青优青论坛论文汇编[C].中华口腔医学会口腔生物医学专业委员会:中华口腔医学会, 2020:2.
[29] 杨琴,杜永秀,翦新春,等. hBD-3在口腔黏膜下纤维性变癌变过程中的表达研究[J]. 实用口腔医学杂志, 2020, 36(5):795-798.
[30] 李毅萍. hBD-2在口腔黏膜下纤维性变、扁平苔藓、口腔鳞癌中表达的研究[J].口腔医学研究, 2012, 28(12):1291-1295.
[31] Yadav A, Desai RS, Bhuta BA, et al.Altered immunohistochemical expression of mast cell tryptase and chymase in the pathogenesis of oral submucous fibrosis and malignant transformation of the overlying epithelium. PLoS One, 2014; 9(5):e98719.
[32] Chaurasia A, Singh N, Sahu D, et al.Comparative Evaluation of role of Lysyl oxidase gene (LOXG473A) expression in pathogenesis and malignant transformation of Oral Submucous Fibrosis[J].Clin Exp Dent. 2019; 11(10):e858-e864.
[33] Shah AM, Jain K, Desai RS, et al.The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study. Head Neck Pathol, 2021; 10.1007
[34] He X, Xu C, Wu X, et al.Expression and methylation of Dickkopf-1 in the pathogenesis and malignant transformation of oral submucous fibrosis. Oral Pathol Med, 2020; 49(8):809-815.
[35] Zhou S, Zhu Y, Mashrah M, et al.Expression pattern of DKK3, dickkopf WNT signaling pathway inhibitor 3, in the malignant progression of oral submucous fibrosis. Oncol Rep, 2017; 37(2):979-985.
[36] Ye MY, Chen MY, Chang YH, et al.Growth-regulated oncogene-α from oral submucous fibrosis fibroblasts promotes malignant transformation of oral precancerous cells. Oral Pathol Med, 2018; 47(9):880-886.
[37] Jyothi Meka N, Ugrappa S, Velpula N, et al.Quantitative Immunoexpression of EGFR in Oral Potentially Malignant Disorders:Oral Leukoplakia and Oral Submucous Fibrosis. Dent Res Dent Clin Dent Prospects, 2015; 9(3):166-174.
[38] Bazarsad S, Zhang X, Kim KY, et al.Identification of a combined biomarker for malignant transformation in oral submucous fibrosis. Oral Pathol Med, 2017; 46(6):431-438.
[39] Patel PN, Thennavan A, Sen S, et al.Translational approach utilizing COX-2, p53, and MDM2 expressions in malignant transformation of oral submucous fibrosis. Oral Sci, 2015; 57(3):169-176.
[40] Angadi PV, Krishnapillai R.Evaluation of PTEN immunoexpression in oral submucous fibrosis: role in pathogenesis and malignant transformation. Head Neck Pathol, 2012; 6(3):314-21. |
